Impact of Regulatory Interventions on Ulipristal Acetate 5 mg (Esmya) Use in Spain: An Interrupted Time‐Series Analysis
Despite RMM had an immediate strong impact on UPA use, the last segment upward trend in the long-term might have been affected by the lack of comparable therapeutic alternatives. Further studies should be performed to confirm the increase trend observed and analyze subsequent measures and additional data.
Authors
- Dolores Montero‐Corominas
- Diana González‐Bermejo (ORCID: https://orcid.org/0000-0002-5771-6072)
- Alfonso Rodríguez‐Pascual
- Belén Castillo‐Cano (ORCID: https://orcid.org/0000-0001-8280-7489)
Institutions
- Agencia Española de Medicamentos y Productos Sanitarios (ES)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/pds.70004
- Citations
- 2
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.93
Funders
- Agencia Española de Medicamentos y Productos Sanitarios